Hot on the heels of positive results for Eli Lilly’s Alzheimer’s disease (AD) drug donanemab, a new blood-based test could soon be hitting the AD clinical space.
The Alzheimer’s Drug Discovery Foundation (ADDF) has seen the clinical promise in ALZpath’s blood-based assay, which is currently restricted to research use only (RUO), investing $1.9m as part of its diagnostics accelerator.
According to ALZpath, a barrier in the widespread uptake of drugs such as Eli Lilly’s donanemab and the recently US Food and Drug Administration (FDA) approved Lecanemab from Biogen and Eisai, is the early diagnosis of disease onset in Alzheimer’s patients.
